Repligen
RGEN----
Repligen (RGEN)
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, an...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Repligen Analyst Rating
View MoreForecast & Rating
Jul 24, 2026Price forecast
$178.0534.93%
Forecast & RatingStrong buy
22analysts
- Strong buy68.18%
- Buy18.18%
- Hold13.64%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · 2 days ago, 08:45 PM
RBC Capital Remains a Buy on Repligen (RGEN)
- Simplywall · Jul 23 at 08:19 AM
Is Repligen (RGEN) Still Undervalued Following Its $1.5b BioLife Deal?
- rttnews · Jul 23 at 03:38 AM
Biotech Stocks At 52-Week Highs - ADVB Surges +73%, BLFS Rises After Acquisition, FBRX, SLN, LBRX
- TradingView · Jul 22 at 04:23 PM
BioLife Solutions to Be Acquired by Repligen for $11.25 Cash Plus 0.1442 Share Per Share
- StockTitan · Jul 21 at 09:00 PM
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media | RGEN Stock News
- prnewswire · Jul 22 at 10:35 AM
11:34 ETShareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholders
